Cargando…
New developments in transcatheter therapy of mitral valve disease
Mitral valve regurgitation (MR) belongs to one of the most common acquired valve diseases in western countries with increasing prevalence in older age. For patients with high perioperative risk and older age prohibitive for valve surgery, the development of transcatheter mitral valve therapies offer...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212154/ https://www.ncbi.nlm.nih.gov/pubmed/32395315 http://dx.doi.org/10.21037/jtd.2019.12.137 |
_version_ | 1783531564615860224 |
---|---|
author | Walther, Claudia Fichtlscherer, Stephan Holubec, Tomas Vasa-Nicotera, Mariuca Arsalan, Mani Walther, Thomas |
author_facet | Walther, Claudia Fichtlscherer, Stephan Holubec, Tomas Vasa-Nicotera, Mariuca Arsalan, Mani Walther, Thomas |
author_sort | Walther, Claudia |
collection | PubMed |
description | Mitral valve regurgitation (MR) belongs to one of the most common acquired valve diseases in western countries with increasing prevalence in older age. For patients with high perioperative risk and older age prohibitive for valve surgery, the development of transcatheter mitral valve therapies offers new options. Assessment of the severity and etiology of MR and thorough imaging of the mitral valve anatomy and pathology are necessary prerequisites for appropriate decision making in the field of transcatheter mitral valve therapies. Different transcatheter repair and replacement techniques are on the market, most of them mimicking surgical techniques. With some techniques (e.g., the MitraClip device), there is good clinical experience (>80,000 devices implanted worldwide), and evidence (three randomized studies), whereas for newer procedures, safety and efficacy data are still very limited. Transcatheter mitral repair and replacement techniques have to be considered as complementary treatment options for high-risk patients indicated by the Heart Teams. The different techniques and devices will be introduced and discussed in the following paper. |
format | Online Article Text |
id | pubmed-7212154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-72121542020-05-11 New developments in transcatheter therapy of mitral valve disease Walther, Claudia Fichtlscherer, Stephan Holubec, Tomas Vasa-Nicotera, Mariuca Arsalan, Mani Walther, Thomas J Thorac Dis Review Article on Interventional Cardiology Mitral valve regurgitation (MR) belongs to one of the most common acquired valve diseases in western countries with increasing prevalence in older age. For patients with high perioperative risk and older age prohibitive for valve surgery, the development of transcatheter mitral valve therapies offers new options. Assessment of the severity and etiology of MR and thorough imaging of the mitral valve anatomy and pathology are necessary prerequisites for appropriate decision making in the field of transcatheter mitral valve therapies. Different transcatheter repair and replacement techniques are on the market, most of them mimicking surgical techniques. With some techniques (e.g., the MitraClip device), there is good clinical experience (>80,000 devices implanted worldwide), and evidence (three randomized studies), whereas for newer procedures, safety and efficacy data are still very limited. Transcatheter mitral repair and replacement techniques have to be considered as complementary treatment options for high-risk patients indicated by the Heart Teams. The different techniques and devices will be introduced and discussed in the following paper. AME Publishing Company 2020-04 /pmc/articles/PMC7212154/ /pubmed/32395315 http://dx.doi.org/10.21037/jtd.2019.12.137 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article on Interventional Cardiology Walther, Claudia Fichtlscherer, Stephan Holubec, Tomas Vasa-Nicotera, Mariuca Arsalan, Mani Walther, Thomas New developments in transcatheter therapy of mitral valve disease |
title | New developments in transcatheter therapy of mitral valve disease |
title_full | New developments in transcatheter therapy of mitral valve disease |
title_fullStr | New developments in transcatheter therapy of mitral valve disease |
title_full_unstemmed | New developments in transcatheter therapy of mitral valve disease |
title_short | New developments in transcatheter therapy of mitral valve disease |
title_sort | new developments in transcatheter therapy of mitral valve disease |
topic | Review Article on Interventional Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212154/ https://www.ncbi.nlm.nih.gov/pubmed/32395315 http://dx.doi.org/10.21037/jtd.2019.12.137 |
work_keys_str_mv | AT waltherclaudia newdevelopmentsintranscathetertherapyofmitralvalvedisease AT fichtlschererstephan newdevelopmentsintranscathetertherapyofmitralvalvedisease AT holubectomas newdevelopmentsintranscathetertherapyofmitralvalvedisease AT vasanicoteramariuca newdevelopmentsintranscathetertherapyofmitralvalvedisease AT arsalanmani newdevelopmentsintranscathetertherapyofmitralvalvedisease AT waltherthomas newdevelopmentsintranscathetertherapyofmitralvalvedisease |